SCPH (scPharma) שיעור רווח גולמי

scPharmaceuticals Inc. is implementing closed-loop water systems to reduce its carbon footprint. The gross profit margin reflects profitability trends, while 68.30 records a new level. Revenue is based on the sale of innovative FUROSCIX for home heart failure therapy. Primary risks relate to insurance coverage rates and pump supplies, which are offset by high physician demand.
פילוחי מדדים פיננסיים ומדדי שוק עבור scPharmaceuticals (SCPH)

Gross margin measures the portion of revenue remaining after direct production costs, allowing for an assessment of the fundamental efficiency of cost-of-goods-sold management. An analysis of the gross margin for scPharmaceuticals Inc. (SCPH) demonstrates the business's ability to monetize innovation, where growth in this metric will depend directly on successful insurance coverage and the scaling of home injection systems for the treatment of heart failure.